Participants received either subcutaneous pramlintide (120 micrograms) or placebo before an ad libitum buffet meal, and caloric intake, meal duration, and subjective appetite ratings were assessed
A study showed that in adults with type 2 diabetes and chronic kidney disease, Ozempic lowers the risk of worsening kidney disease, kidney failure (end-stage kidney disease), and death due to cardiovascular disease
Some patients transition to a lower maintenance dose after reaching their goal
Pretorius E, du Plooy JN, Bester J
Key red flags: COAs with no date, no batch number, or originating from the vendor's own lab
[5] [6] It is important to note that while Ozempic may cause weight loss, it is not licensed for weight management in the UK (Wegovy is the semaglutide brand licensed for weight management)